240 related articles for article (PubMed ID: 33759290)
1. Evolution of estimated glomerular filtration rate in human immunodeficiency virus and hepatitis C virus-coinfected patients receiving sofosbuvir-based direct-acting antivirals and antiretroviral therapy.
Liu CH; Sun HY; Hsieh SM; Liu WC; Sheng WH; Liu CJ; Su TH; Tseng TC; Chen PJ; Hung CC; Kao JH
J Viral Hepat; 2021 Jun; 28(6):887-896. PubMed ID: 33759290
[TBL] [Abstract][Full Text] [Related]
2. Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals.
Liu CH; Lee MH; Lin JW; Liu CJ; Su TH; Tseng TC; Chen PJ; Chen DS; Kao JH
J Hepatol; 2020 May; 72(5):839-846. PubMed ID: 31790766
[TBL] [Abstract][Full Text] [Related]
3. Serial changes in renal indices in chronic HCV patients with and without HIV co-infection receiving sofosbuvir and tenofovir-based therapies.
Abdel Alem S; El Garhy N; El Khateeb E; Khalil M; Cordie A; Elsharkawy A; Fouad R; Esmat G; Abdelbary MS
Trans R Soc Trop Med Hyg; 2023 Apr; 117(4):285-296. PubMed ID: 36397681
[TBL] [Abstract][Full Text] [Related]
4. Evolution of estimated glomerular filtration rate in HIV/HCV-coinfected patients who received direct-acting antivirals: A multicenter retrospective study.
Tsai CY; Chen GJ; Tsai CS; Liou BH; Yang CJ; Tsai HC; Lin CY; Huang SH; Lin KY; Wang NC; Chen TC; Lee CH; Hung CC;
J Microbiol Immunol Infect; 2023 Aug; 56(4):718-728. PubMed ID: 37045634
[TBL] [Abstract][Full Text] [Related]
5. Nephrotoxicity Associated with Concomitant Use of Ledipasvir-Sofosbuvir and Tenofovir in a Patient with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection.
Bunnell KL; Vibhakar S; Glowacki RC; Gallagher MA; Osei AM; Huhn G
Pharmacotherapy; 2016 Sep; 36(9):e148-53. PubMed ID: 27459733
[TBL] [Abstract][Full Text] [Related]
6. Incidence of Acute Kidney Injury in Patients Coinfected with HIV and Hepatitis C Virus Receiving Tenofovir Disoproxil Fumarate and Ledipasvir/Sofosbuvir in a Real-World, Urban, Ryan White Clinic.
Michal JL; Rab S; Patel M; Kyle AW; Miller LS; Easley KA; Kalapila AG
AIDS Res Hum Retroviruses; 2018 Aug; 34(8):690-698. PubMed ID: 29766745
[TBL] [Abstract][Full Text] [Related]
7. Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections.
Sun HY; Cheng CY; Lin CY; Yang CJ; Lee NY; Liou BH; Tang HJ; Liu YM; Lee CY; Chen TC; Huang YC; Lee YT; Tsai MJ; Lu PL; Tsai HC; Wang NC; Hung TC; Cheng SH; Hung CC
World J Gastroenterol; 2022 Mar; 28(11):1172-1183. PubMed ID: 35431505
[TBL] [Abstract][Full Text] [Related]
8. Glomerular filtration rate change during chronic hepatitis C treatment with Sofosbuvir/Ledipasvir in HCV/HIV Coinfected patients treated with Tenofovir and a boosted protease inhibitor: an observational prospective study.
Soeiro CASP; Gonçalves CAM; Marques MSC; Méndez MJV; Tavares APRA; Horta AMLMFCA; Sarmento-Castro RMDR
BMC Infect Dis; 2018 Aug; 18(1):364. PubMed ID: 30075765
[TBL] [Abstract][Full Text] [Related]
9. Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection.
Liu CH; Sun HY; Liu CJ; Sheng WH; Hsieh SM; Lo YC; Liu WC; Su TH; Yang HC; Hong CM; Tseng TC; Chen PJ; Chen DS; Hung CC; Kao JH
Aliment Pharmacol Ther; 2018 Jun; 47(12):1690-1698. PubMed ID: 29665069
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of pan-genotypic sofosbuvir and velpatasvir in patients with hepatitis C and HIV coinfection on dolutegravir-based antiretroviral therapy.
De A; Charak S; Bhagat N; Rathi S; Verma N; Premkumar M; Taneja S; Sharma A; Goel K; Singh V; Duseja A
J Viral Hepat; 2023 Sep; 30(9):740-745. PubMed ID: 37260083
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C Virus Treatment Response to Direct-acting Antivirals Among Adolescents With HIV/HCV Coinfection: Real-world Data From Ukraine.
Malik F; Malyuta R; Volokha A; Bailey H; Collins IJ; Thorne C;
Pediatr Infect Dis J; 2022 May; 41(5):417-419. PubMed ID: 35067642
[TBL] [Abstract][Full Text] [Related]
12. Impact of interferon-free regimens on the glomerular filtration rate during treatment of chronic hepatitis C in a real-life cohort.
Álvarez-Ossorio MJ; Sarmento E Castro R; Granados R; Macías J; Morano-Amado LE; Ríos MJ; Merino D; Álvarez EN; Collado A; Pérez-Pérez M; Téllez F; Martín JM; Méndez J; Pineda JA; Neukam K;
J Viral Hepat; 2018 Jun; 25(6):699-706. PubMed ID: 29377515
[TBL] [Abstract][Full Text] [Related]
13. Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir.
Gianotti N; Galli L; Poli A; Salpietro S; Nozza S; Carbone A; Merli M; Ripa M; Lazzarin A; Castagna A
Medicine (Baltimore); 2016 May; 95(22):e3780. PubMed ID: 27258510
[TBL] [Abstract][Full Text] [Related]
14. Successful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C virus infection.
Grant JL; Hawkins C; Brooks H; Palella FJ; Koppe SW; Abecassis MM; Stosor V
AIDS; 2016 Jan; 30(1):93-8. PubMed ID: 26731756
[TBL] [Abstract][Full Text] [Related]
15. Effect of P-glycoprotein and Cotreatment with Sofosbuvir on the Intestinal Permeation of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide Fumarate.
Huliciak M; Lhotska I; Kocova-Vlckova H; Halodova V; Dusek T; Cecka F; Staud F; Vokral I; Cerveny L
Pharm Res; 2023 Sep; 40(9):2109-2120. PubMed ID: 37594591
[TBL] [Abstract][Full Text] [Related]
16. Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration.
Townsend K; Meissner EG; Sidharthan S; Sampson M; Remaley AT; Tang L; Kohli A; Osinusi A; Masur H; Kottilil S
AIDS Res Hum Retroviruses; 2016 May; 32(5):456-62. PubMed ID: 26559180
[TBL] [Abstract][Full Text] [Related]
17. Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on estimated glomerular filtration rate slope in patients with HIV: A retrospective observational study.
Hikasa S; Shimabukuro S; Hideta K; Higasa S; Sawada A; Tokugawa T; Tanaka K; Yanai M; Kimura T
J Infect Chemother; 2022 Mar; 28(3):396-400. PubMed ID: 34896027
[TBL] [Abstract][Full Text] [Related]
18. Brief Report: Effect of Antiretroviral Switch From Tenofovir Disoproxil fumarate to Tenofovir Alafenamide on Alanine Aminotransferase, Lipid Profiles, and Renal Function in HIV/HBV-Coinfected Individuals in a Nationwide Canadian Study.
Sarowar A; Coffin CS; Fung S; Wong A; Doucette K; Truong D; Conway B; Haylock-Jacobs S; Ramji A; Hansen BE; Janssen HLA; Cooper C
J Acquir Immune Defic Syndr; 2022 Dec; 91(4):368-372. PubMed ID: 36288543
[TBL] [Abstract][Full Text] [Related]
19. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.
Milazzo L; Lai A; Calvi E; Ronzi P; Micheli V; Binda F; Ridolfo AL; Gervasoni C; Galli M; Antinori S; Sollima S
HIV Med; 2017 Apr; 18(4):284-291. PubMed ID: 27477612
[TBL] [Abstract][Full Text] [Related]
20. Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison.
Swallow E; Song J; Yuan Y; Kalsekar A; Kelley C; Peeples M; Mu F; Ackerman P; Signorovitch J
Clin Ther; 2016 Feb; 38(2):404-12. PubMed ID: 26839044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
